TY - JOUR
T1 - Paclitaxel
T2 - Application in Modern Oncology and Nanomedicine-Based Cancer Therapy
AU - Sharifi-Rad, Javad
AU - Quispe, Cristina
AU - Patra, Jayanta Kumar
AU - Singh, Yengkhom Disco
AU - Panda, Manasa Kumar
AU - Das, Gitishree
AU - Adetunji, Charles Oluwaseun
AU - Michael, Olugbenga Samuel
AU - Sytar, Oksana
AU - Polito, Letizia
AU - Živković, Jelena
AU - Cruz-Martins, Natália
AU - Klimek-Szczykutowicz, Marta
AU - Ekiert, Halina
AU - Choudhary, Muhammad Iqbal
AU - Ayatollahi, Seyed Abdulmajid
AU - Tynybekov, Bekzat
AU - Kobarfard, Farzad
AU - Muntean, Ana Covilca
AU - Grozea, Ioana
AU - Daştan, Sevgi Durna
AU - Butnariu, Monica
AU - Szopa, Agnieszka
AU - Calina, Daniela
N1 - Publisher Copyright:
© 2021 Javad Sharifi-Rad et al.
PY - 2021
Y1 - 2021
N2 - Paclitaxel is a broad-spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent-induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half-life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.
AB - Paclitaxel is a broad-spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree Taxus brevifolia Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent-induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half-life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent.
UR - http://www.scopus.com/inward/record.url?scp=85118573577&partnerID=8YFLogxK
U2 - 10.1155/2021/3687700
DO - 10.1155/2021/3687700
M3 - Review article
C2 - 34707776
AN - SCOPUS:85118573577
SN - 1942-0900
VL - 2021
JO - Oxidative Medicine and Cellular Longevity
JF - Oxidative Medicine and Cellular Longevity
M1 - 3687700
ER -